Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1955

Sort by

Sort Order Select

Journal Articles

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

Blood Adv (2025) 9 (15): 3739–3749.

https://doi.org/10.1182/bloodadvances.2024015571

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Blood Adv (2025) 9 (15): 3665–3675.

https://doi.org/10.1182/bloodadvances.2024015180

Published: 2025

Includes: Supplemental data

Journal Articles

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Adv (2025) 9 (15): 3694–3705.

https://doi.org/10.1182/bloodadvances.2024015262

Published: 2025

Includes: Supplemental data

Journal Articles

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results

Bruce D. Cheson, Nancy L. Bartlett, Betsy Knopf, Hun J. Lee, Ranjana H. Advani, Beth Christian, Catherine S. Diefenbach, Tatyana A. Feldman, Stephen M. Ansell

Blood Adv (2025) 9 (15): 3750–3753.

https://doi.org/10.1182/bloodadvances.2025016470

Published: 2025

Journal Articles

Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease

Lana Mucalo Katunaric, Shuang Jia, Ashima Singh, Mark F. Roethle, Julie A. Panepinto, David C. Brousseau, Martin J. Hessner, Amanda M. Brandow

Blood Adv (2025) 9 (15): 3790–3800.

https://doi.org/10.1182/bloodadvances.2024015085

Published: 2025

Includes: Supplemental data

Journal Articles

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial

Blood Adv (2025) 9 (15): 3728–3738.

https://doi.org/10.1182/bloodadvances.2024015102

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O’Brien

Blood Adv (2025) 9 (15): 3801–3809.

https://doi.org/10.1182/bloodadvances.2024015417

Published: 2025

Journal Articles

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

Kellen Cristine Tjioe, Marisol Miranda-Galvis, Kenza Mamouni, Thalyta Freitas, Muhannad Sharara, Brenda Santellano, Claudia Guillén-Lopez, Jorge E. Cortes

Blood Adv (2025) 9 (15): 3810–3813.

https://doi.org/10.1182/bloodadvances.2024014340

Published: 2025

Includes: Supplemental data

Journal Articles

ESCALATing care? Eltrombopag in pediatric aplastic anemia

Joshua Glass, Emma M. Groarke

Blood Adv (2025) 9 (15): 3819–3820.

https://doi.org/10.1182/bloodadvances.2025016872

Published: 2025

Journal Articles

Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy

Blood Adv bloodadvances.2025016298.

https://doi.org/10.1182/bloodadvances.2025016298

Published: 2025

Journal Articles

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML

Pau Montesinos, Dylan M. Marchione, Christian Récher, Michael Heuser, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Adriana E Tron, Jianan Hui, Diego A. Gianolio, Sung Choe, Prapti A. Patel, Stéphane De Botton, Courtney D. DiNardo, Hartmut Döhner

Blood Adv bloodadvances.2025016399.

https://doi.org/10.1182/bloodadvances.2025016399

Published: 2025

Includes: Supplemental data

Journal Articles

Getting closer to hemophilia gene therapy for all?

Ulrike M. Reiss

Blood Adv (2025) 9 (14): 3629–3630.

https://doi.org/10.1182/bloodadvances.2025016642

Published: 2025

Journal Articles

Untangling profiles of postthrombotic syndrome using unsupervised machine learning

Aaron F. J. Iding, Vincent ten Cate, Hugo ten Cate, Philipp S. Wild, Arina J. ten Cate-Hoek

Blood Adv (2025) 9 (14): 3631–3641.

https://doi.org/10.1182/bloodadvances.2025015829

Published: 2025

Includes: Supplemental data

Journal Articles

Reassessing the Villalta score’s use of signs and symptoms

Steven H. Yale, Halil Tekiner, Regina Wilson, Eileen S. Yale

Blood Adv (2025) 9 (14): 3642–3643.

https://doi.org/10.1182/bloodadvances.2025016750

Published: 2025

Journal Articles

Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up

Tatyana Gavrilova, Lori McIntyre, Stephanie L Goff, James C. Yang, Danielle A Natrakul, Steven A Rosenberg, James N. Kochenderfer, Jennifer N Brudno

Blood Adv bloodadvances.2025016504.

https://doi.org/10.1182/bloodadvances.2025016504

Published: 2025

Includes: Supplemental data

Journal Articles

Long term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Michael Sang Hughes, Samuel S Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani

Blood Adv bloodadvances.2025016731.

https://doi.org/10.1182/bloodadvances.2025016731

Published: 2025

Includes: Supplemental data

Journal Articles

Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial

Raphael E. Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman E Seshan, Swetha Thiruvengadam, Niloufer Khan, Jeremy S. Abramson, Steven M Horwitz, Matthew J. Matasar, Colette N Owens, Ildefonso Ismael Rodriguez-Rivera, David Strauss, Timothy S. Pardee, Sanjeev Luther, Sabrina Saboukoulou, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood Adv bloodadvances.2025016168.

https://doi.org/10.1182/bloodadvances.2025016168

Published: 2025

Includes: Supplemental data

Journal Articles

Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis

Alberto Guijosa, Andres Ramirez-Gamero, Shayna Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Steven P. Treon, Jorge J. Castillo

Blood Adv bloodadvances.2025016536.

https://doi.org/10.1182/bloodadvances.2025016536

Published: 2025

Journal Articles

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia

Jorge J. Castillo, Alberto Guijosa, John N. Allan, Tanya Siddiqi, Ranjana H Advani, Catherine Flynn, Kirsten E. Meid, Nina Budano, Julia Nguyen, Andres Ramirez-Gamero, Nicholas Tsakmaklis, Zachary R Hunter, Christopher J Patterson, Steven P. Treon, Shayna Sarosiek

Blood Adv bloodadvances.2025016890.

https://doi.org/10.1182/bloodadvances.2025016890

Published: 2025

Journal Articles

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

Jorge E. Cortes, Jay Yang, Gail J Roboz, Shira Naomi Dinner, Eunice S. Wang, Andrew H Wei, Hua Tian, Francois di Trapani, Maria R Baer, William B Donnellan, Justin M Watts

Blood Adv bloodadvances.2025016718.

https://doi.org/10.1182/bloodadvances.2025016718

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results

Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval

ESCALATing care? Eltrombopag in pediatric aplastic anemia

Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML

Getting closer to hemophilia gene therapy for all?

Untangling profiles of postthrombotic syndrome using unsupervised machine learning

Reassessing the Villalta score’s use of signs and symptoms

Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up

Long term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial

Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only